Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 10/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908846 | 0.96 | S1PR2 (0.56) | S1PR2POLBKDM4EHSD17B10HRH1 | |
| SCHEMBL23966895 | 0.92 | S1PR2 (0.48) | S1PR2POLBKDM4EHSD17B10HRH1 | |
| SCHEMBL23966605 | 0.89 | S1PR2 (0.55) | S1PR2POLBKDM4EHSD17B10 | |
| SCHEMBL23908809 | 0.87 | S1PR2 (0.59) | S1PR2POLBKDM4EHSD17B10KDM1A | |
| SCHEMBL23966623 | 0.85 | S1PR2 (0.54) | S1PR2POLBKDM4EHSD17B10 | |
| SCHEMBL23909046 | 0.84 | S1PR2 (0.61) | S1PR2POLBKDM4EHSD17B10 | |
| SCHEMBL23908787 | 0.83 | S1PR2 (0.58) | S1PR2POLBKDM4EHSD17B10KDM1A | |
| SCHEMBL23908852 | 0.83 | S1PR2 (0.57) | S1PR2POLBKDM4EHSD17B10 | |
| SCHEMBL23908878 | 0.83 | S1PR2 (0.64) | S1PR2POLBKDM4EHSD17B10 | |
| SCHEMBL23966642 | 0.83 | S1PR2 (0.63) | S1PR2POLBKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |